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In this study in Rhesus macaques, we tested whether IL-12 or IL-15 in a DNA prime-oral Listeria boost amplifies the SIV-Gag-specific CD8
mucosal response. SIV-specific CD8 T cells were demonstrated in the peripheral blood (PB) in all test vaccine groups, but not the control group.
SIV-Gag-specific CD8 T cells in the PB expressed α4β7 integrin, the gut-homing receptor; a minor subset co-express αEβ7 integrin. SIV-Gag-
specific CD8 T cells were also detected in the gut tissue, intraepithelial (IEL) and lamina propria lymphocytes (LPL) of the duodenum and ileum.
These cells were characterized by high levels of β7 integrin expression and a predominance of the effector memory phenotype. Neither Il-12 nor
IL-15 amplified the frequency of SIV-specific CD8 T cells in the gut. Thus, the DNA prime-oral Listeria boost strategy induced a mucosal SIV-
Gag-specific CD8 T cell response characterized by expression of the α4β7 integrin gut-homing receptor.
© 2006 Published by Elsevier Inc.Keywords: Vaccination; Mucosal immunity; Adhesion moleculeIntroduction
HIV is a major health problem in the western world and has
reached pandemic proportions in third world countries. The
most common mode of infection is sexual transmission through
mucosal tissue. Furthermore, active replication of HIV (Fackler
et al., 1998; Kotler et al., 1991; Markowitz et al., 1999; Smith et
al., 1994) and eradication of activated/memory CD4 T cells
(Schneider et al., 1994, 1995; Veazey et al., 1998) occurs in the
GALT early in HIV infection. Therefore, a successful HIV
vaccine needs to induce a strong mucosal immune response to⁎ Corresponding author. Fax: +1 215 573 4666.
E-mail address: yvonne@mail.med.upenn.edu (Y. Paterson).
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doi:10.1016/j.virol.2006.06.036prevent mucosal infection and the rapid reduction of CD4 T
cells in the GALT. SIV infection in rhesus macaque monkeys
has been used extensively to model HIV infection in humans
and to test vaccines. Prior studies demonstrated that the target
population for SIV infection in the GALT (Li et al., 2005),
reduction in memory CD4 T cells (Reynolds et al., 2005) and
SIV-specific CD8 T cell responses are similar to HIV in humans
(Mattapallil et al., 2004; Veazey et al., 2000, 2001; Vingert et
al., 2003). Containment of SIVmac251 infection in vaccinated
rhesus macaques correlates with the magnitude of SIV-specific
CD4 and CD8 T cell responses (Hel et al., 2002). In addition,
SIV disease progression is thought to be associated with
impairment of SIV-specific T cell function (Hel et al., 2001).
SIV vaccines have been tested in rhesus macaques with a focus
on inducing mucosal (Evans et al., 2003; Zhao et al., 2003) or
systemic (Radaelli et al., 2003) immunity. Mucosal immunity
Table 1
Immunization schedule and monkey test/control groups
Group Weeks
0, 4, 8
Weeks
16 and 20
Weeks
24 and 38
Monkey
no.
Haplotype
1 DNA Lm Gag
and Env
oral
3×1010/dose
Lm Gag
and Env
oral 3×1011
4113 A08, B01
2 mg SIVgag 4107 A01, A02, B17
2 mg SIVenv 4110 A01
4111 A02
4116 A02, A08, B01
2 DNA Lm Gag
and Env
vectors oral
3×1010/dose
Lm Gag
and Env
vectors oral
3×1011
4104 A08, B01
2 mg SIVgag 4105 A01, A02
2 mg SIVenv 4108 Unknown
+IL-15
plasmid
4109 A08
4114 A02
3 DNA Lm Gag
and Env
vectors oral
3×1010/dose
Lm Gag
and Env
vectors oral
3×1011
4112 Unknown
2 mg SIVgag 4117 A01, A08
2 mg SIVenv 4118 A02
+IL-12
plasmid
4120 A02, B01
4123 A02
Control DNA Lm-E7
Oral
3×1010/dose
Lm-E7
Oral 3×1011
4106 A02, A08
Variola 4115 B01
4119 A01,A02, B01
4121 Unknown
4122 B01
Rhesus monkeys were sorted into 5 individuals per group to include an even
spread of MamuA*01 and MamuA*02 haplotypes as well as non-A01/A02
haplotypes. As a result each test vaccine and control group had haplotype-
negative and -positive members for the SIV-Gag tetramers. Details of the DNA
vaccine for each test and control group are given; the same dose and construct
was used for all test vaccine groups for the oral Listeria.
300 P. Neeson et al. / Virology 354 (2006) 299–315can be induced by oral immunization; effector T cells migrate
locally from inductive to effector sites in the gut as well as to
other mucosal effector sites of the body (Cromwell et al., 2000;
Evans et al., 2003).
We have been using Listeria as a vaccine vector to deliver
target antigens as a vaccine for HIV, reviewed in Paterson and
Johnson (2004) or tumors, reviewed in Paterson and Maciag
(2005). The Listeria-based vaccines are capable of inducing a
powerful cell-mediated immune response to target antigens.
This is due to a number of factors including the innate
immune response to Listeria and its unique life cycle. The
bacterium has an intracellular lifecycle that intersects with
both MHC class I and II processing pathways; proteins
secreted by a Listeria vector can be processed through both
the cytosolic or endosomal compartments onto MHC class I or
II, contributing to both a CD4 and CD8 response to the target
antigen (Bishop and Hinrichs, 1987; De Libero and Kauf-
mann, 1986) with a Th1 phenotype (Mata and Paterson,
1999). In a recent study we demonstrated that a SIV DNA
prime-Listeria boost immunization strategy induced a cellular
response capable of partial suppression of SIV239 viral
replication (Boyer et al., 2005b). Also, in prior studies, IL-
12 (Boyer et al., 2005a; Egan et al., 2005) or IL-15 (Kutzler et
al., 2005) plasmids enhanced the SIV-Gag-specific T cell
response to the SIV-Gag DNA vaccine (Calarota et al., 2003).
Therefore, we designed a study to see whether a DNA prime-
oral Listeria boost combined with either IL-15 or IL-12
plasmid vaccines would amplify mucosal CD8 T cell
responses to SIV. In order to explore this hypothesis, we
used multi-parameter flow cytometry and ELISPOT to
measure the CD8 T cell responses to the DNA prime-oral
Listeria strategy in the peripheral blood, lymph nodes and
the gut. We used flow cytometry to assess the binding of SIV-
Gag tetramers to CD8 T cells in conjunction with the
expression of beta 7 integrin. Beta 7 integrin is an adhesion
molecule that facilitates normal intestinal immune cell
trafficking to the gut (Butcher et al., 1999; Kuklin et al.,
2000; Lefrancois et al., 1999; von Andrian and Mackay, 2000)
and serves as a ‘gut-homing’ marker on T cells. In addition,
we investigated the functional state of the CD8 T cells in each
sample by examining expression of CD28 and CD95. This
enabled us to assess the relative frequency of CD8 T cells in a
naive or effector memory state (Pitcher et al., 2002). We found
that the DNA prime-oral Listeria boost strategy induced a
SIV-Gag-specific CD8 T cell response in the gut, lymph nodes
and peripheral blood. This response was accompanied by a
change in PB CD8 T cell subsets, including a decrease in the
frequency of naive and an increase in effector memory cells.
Although there was an increase in the number of monkeys
responding to SIV-Gag in the PB in the vaccine group which
received IL-15, there was no difference in the magnitude (the
% of CD8 T cells with elevated tetramer binding or the
number of spot forming cells by IFN-γ ELISPOT) of SIV-
Gag responses by CD8 T cells between vaccine groups.
Although the inclusion of IL-12 clearly enhanced the DNA
priming of SIV-specific CD8 T cells in the PB and IL-15
enhanced the response to the first Listeria boost, the inclusionof these cytokines in the DNA vaccine prime did not enhance
the final vaccine response.
Results
The aim of this study was twofold; firstly, to assess
whether the DNA prime-oral Listeria boost immunization
strategy induces a SIV-specific mucosal response; and
secondly, to assess whether this mucosal response could
be amplified by IL-12 or IL-15. Therefore, initially monkeys
were sorted into four immunization groups of five
individuals, based on their MHC class I haplotype. Test
groups were primed with three rounds of SIV gag and env
DNA vaccine i.m. followed by oral Listeria boost four times
(see Table 1 for details). Each vaccine group contained
individuals that express MHC class I haplotype MamuA*01
and/or MamuA*02, as well as controls that were non-A01/
A02. Following the immunization, samples were harvested
from the peripheral blood, lymph nodes and gut tissue to
evaluate the immune response.
Initially, we found that all test vaccines induced SIV-Gag-
and Env-specific CD8 T cells (detected by IFN-gamma
ELISPOT) in the PB, 14 days after the 1st three DNA
vaccines and the 1st Listeria boost. However after the 2nd
Listeria boost the SIV Env-specific CD8 T cells had
decreased markedly (Fig. 1Aii), we ceased testing for SIV
Env CD8 response in the PB from this point. Statistical
Fig. 1. DNA prime-Listeria boost immunization-induced SIV-Gag-specific CD8 Tcells in the peripheral blood and axillary lymph node but not the mesenteric lymph node. SIV-Gag-specific CD8 Tcells were detected by
ELISPOT for IFN-gamma secretion in response to SIV-Gag and SIV Env overlapping peptides (as per methods). The ELISPOT assay was performed on (A) PBMC's harvested during DNA and Listeria immunizations,
samples were collected 14 days after each immunization except 3rd LmD7, which was collected 7 days after the 3rd Listeria immunization (B) PBMCs harvested days 7 and 14 post-final Listeria immunization, and (C)
PBMCs, axillary and mesenteric lymph nodes harvested day 14 post-final Listeria immunization. Samples are positive when they have >50 SFC per million PBMCs. Samples marked by an asterisk (*) have >50%
reduction in SFC/million PBMCs after CD8 depletion of the PBMCs. In (A) the ELISPOT data has been plotted as the mean±standard error for Gag (Ai) and Env (Aii) responses for each immunization group over the
time course of the DNA prime-Listeria boost; whereas in panels B, C the individual data for each monkey has been plotted on samples collected day 14 after the last Listeria boost.
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302 P. Neeson et al. / Virology 354 (2006) 299–315analysis of the SIV Env-specific CD8 T cell response by the
non-parametric test (Kruskal-Wallis) demonstrated a signifi-
cant difference between vaccine groups at two time points only.
This occurred following the 3rd DNA vaccine ( p=0.012) and
the first Listeria boost ( p=0.046). Subsequently, a Mann–
Whitney test was used to demonstrate a significant difference
between the control and test vaccine groups at two im-
munization points (post-3rd DNA and -1st Listeria immuniza-
tion). The DNA only ( p=0.008), DNA+IL-12 ( p=0.008) and
DNA+IL15 ( p=0.05) vaccine groups were significantly
different to the control group post-3rd DNA immunization.
In addition, after the 1st Listeria immunization the DNA+IL-
12 ( p=0.021) and DNA+IL-15 were significantly different to
the control.
The SIV-Gag responses persisted through to the 3rd
Listeria boost (Fig. 1Ai), at this time point the SIV-Gag
response was detected at day 7 and this decreased to day 14
(Fig. 1Ai). Statistical analysis of the SIV-Gag-specific CD8
T cell response by the Kruskal-Wallis test showed a
significant difference between vaccine groups following the
3rd DNA vaccine and following the 3rd Listeria dose.
Subsequent analysis by Mann–Whitney of the data at these
time points showed that all three test vaccines were sig-
nificantly different to the control vaccine. Following the 3rd
DNA immunization compared to the control group the
vaccine groups DNA only ( p= 0.047), DNA+ IL-12
( p=0.047) and DNA+IL-15 ( p=0.028) were all signifi-
cantly different. Also, 7 days following the 3rd Listeria
dose, the vaccine groups DNA only ( p=0.016), DNA+IL-Fig. 2. DNA prime-Listeria boost vaccine induces SIV-gag-specific CD8 T cells that a
the binding of SIV-Gag tetramer and surface expression of beta 7 integrin on CD8 T c
followed by dual expression of CD3 and CD8.12 ( p=0.009) and DNA+IL-15 ( p=0.047) were also
significantly different to the control group.
DNA prime-Listeria boost induce SIV-Gag-specific T cells in
the peripheral blood
Peripheral blood samples were collected on days seven and
fourteen after the last Listeria boost and the presence of SIV-
Gag-specific CD8 T cells was assessed by ELISPOT (Fig.
1B) and tetramer analysis (Fig. 2 and Supplementary Table
1). The ELISPOT data in Fig. 1B shows that the PBMCs
secrete IFN-gamma in all three test groups. Three responders
out of five monkeys were found in DNA and DNA plus IL-
12 vaccine groups, whereas four responders out of five
monkeys were detected in the DNA plus IL-15 group.
Furthermore, depletion of CD8 T cells reduces the number of
cells secreting IFN-gamma by >50% in all monkeys that were
positive (marked by a * in Fig. 1B), indicating that the CD8
T cells are significant contributors to the IFN-gamma
secretion by PBMCs as detected by ELISPOT. When the
ELISPOT data for SIV-Gag-specific CD8 T cells in the PB at
day 14 was collated with the same data set from the lymph
node samples (Fig. 1C) we found two responders (monkeys
4120 and 4112) in the DNA+IL-15 group who had SIV-Gag-
specific CD8 T cells in the PB and the axillary lymph node.
Conversely, there were a number of monkeys with circulating
SIV-Gag-specific CD8 T cells (by ELISPOT) in the PB (4113,
4116, 4109, 4114, 4118 and 4123) that did not have evidence
of a response by this assay in either lymph nodes (Fig. 1C).re present in the periphery. Dot plots from representative samples demonstrating
ells from PB. CD8 T cells were first selected based on a lymphocyte scatter gate
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specific CD8 T cells in the mesenteric lymph node of
immunized monkeys (Fig. 1C). Representative dot plots in
Fig. 2 demonstrate the gating strategy to define CD8 T cells,
followed by A01 or A02 tetramer binding to the CD8 T cells
in the peripheral blood taken on days seven and fourteen
post-last oral Listeria boost. Monkey 4120 had positive
tetramer binding with the A02 SIV-Gag tetramer on both days
seven and fourteen; in contrast monkey 4105 has positive
binding only on day seven. The frequency of SIV-Gag-
specific CD8 T cells in the PB is shown in Supplementary
Table 1, a summary of the A01 and A02 SIV-Gag tetramer
binding in all peripheral blood samples is shown in Table 2.
These data show that each test vaccine-induced SIV-Gag-
specific CD8 T cells, whereas CD8 T cells induced by the
control vaccine were negative for A01/A02 SIV-Gag tetramer.
When tetramer binding to only A01 or A02 monkeys were
assessed, three out of four monkeys were positive in group
one, both monkeys were positive in group two and three of
four were positive in group three. The A02 monkeys positive
for tetramer analysis were positive on both days seven and
fourteen after the last Listeria boost in five of six monkeys.
In contrast, positive binding of the A01 SIV-Gag tetramer was
detected only on day seven samples.
When the SIV-Gag ELISPOT and tetramer data from PB
samples were collated (see Table 2), we demonstrated SIV-Gag-
specific CD8 T cells in 5/5 monkeys in group one, 4/5 monkeys
in group two and 4/5 monkeys in group three. Furthermore,
individual monkeys within these vaccine groups were demon-
strated to be either ELISPOT+/Tetramer+, ELISPOT−/Table 2
Summary of SIV-gag-specific T cells in the PB, the gut, draining and distant lymph
Group Immunization Monkey Haplotype PBMC
D7 T D7 E
1 DNA prime 4113 A08, B01 − −
Lm boost 4107 A01, A02, B17 + −
No cytokine 4110 A01 + +
4111 A02 + −
4116 A02, A08, B01 − −
2 DNA prime 4104 A08, B01 − −
Lm boost 4108 none − +
IL-12 4109 A08 − +
4105 A01, A02 + −
4114 A02 − −
3 DNA prime 4112 none − −
Lm boost 4117 A01, A08 − −
IL-15 4118 A02 + −
4120 A02, B01 + +
4123 A02 + −
4 Control DNA 4121 none − −
LmE7 boost 4122 B01 − −
4115 B01 − −
4106 A02, A08 − −
4119 A01, A02, B01 − −
PBMC samples were collected either day 7 (D7) or day 14 (D14) post-Listeria boost,
were all collected on day 14. Sections of jejunum and ileumwere processed to recover i
analysis only was performed on these samples. Tetramer binding was calculated as the
restricted tetramer GY9. This was calculated by the addition of the upper left and uppe
PB and Fig. 3 for tissue samples. Positive tetramer binding or ELISPOT results wereTetramer+ or ELISPOT+/Tetramer−. The ELISPOT−/Tetramer+
group are likely to represent SIV-Gag-specific CD8 T cells that
are secreting cytokines other than IFN-gamma, which has been
observed previously (Loffredo et al., 2004). Whereas, the
ELISPOT+/Tetramer− group represents monkeys that are
responding to epitopes other than those bound by the A01 or
A02 tetramer.
DNA prime-Listeria boost immunization induces
SIV-Gag-specific CD8 T cells in the gut, draining and
distal lymph nodes
In order to assess the mucosal response to DNA prime-oral
Listeria boost, samples were collected from the gut (jejunum
and ileum), mesenteric (draining lymph node) and axillary
(distant lymph node) lymph nodes. The gut tissue was
separated into two fractions, intra-epithelial lymphocytes
(IEL) and lamina propria lymphocytes (LPL). SIV-Gag
tetramer binding was assessed on all samples; whereas IFN-
gamma ELISPOT was only performed on lymph node
samples. Representative dot plots depicting positive binding
of the A02 SIV-Gag tetramer to CD8 T cells for the lymph
nodes and gut tissue are shown in Fig. 3, the frequency of
SIV-Gag-specific CD8 T cells in each sample is shown in
Supplementary Table 2. In general, higher levels of SIV-Gag
tetramer binding were seen in the gut tissue of monkeys than
in either of the two lymph nodes. Monkey 4123 was the only
individual to respond to the DNA prime-oral Listeria boost
immunization in all samples tested except the MLN (see
Table 2). Furthermore, pooling the gut tissue results showednodes detected by tetramer staining (T) and ELISPOT (E)
ALN MLN Jejunum Ileum
D14 T D14 E T E T E IEL LPL IEL LPL
− + − − − − − − − −
− − + − + − + − − −
− − + + + − − − − +
− − − − + − − + − +
− + − − − − − − − −
− − − − − − − − − −
− − − − − − −
− + − − − − − − − −
− − + − + − + − + +
+ + − − − − + + − +
− + − − − − − − −
− − + + + − − − − +
− + − − − + − − +
+ + − − − − − − − +
+ + − + − − + + + +
− −
− − − − − − − − −
− − − − − − − − − −
− − − − − − − − − −
− −
whereas axillary LN (ALN), mesenteric lymph node (MLN), jejunum and ileum
ntraepithelial lymphocytes (IEL) and lamina propria lymphocytes (LPL), tetramer
% CD8 Tcells staining positive for the A01-restricted tetramer CM9 or the A02-
r right quadrants for the beta 7 versus tetramer binding dot plots, as per Fig. 2 for
determined as per the methods and is represented by “+”, a negative result “−”.
Fig. 3. DNA prime-Listeria boost vaccine induces SIV-gag-specific CD8 T cells that are present in the gut and lymph nodes. Dot plots from representative samples
(monkey no. in brackets) demonstrating the binding of SIV-Gag tetramer and surface expression of beta 7 integrin on CD8 Tcells from gut tissue (jejunum and ileum),
mesenteric and axillary lymph nodes. CD8 T cells were selected based on a lymphocyte scatter gate and dual expression of CD3 and CD8.
304 P. Neeson et al. / Virology 354 (2006) 299–315elevated SIV-Gag tetramer binding to CD8 T cells in 4/5
possible responders in group one, 2/2 in group two and 3/4 in
group three. No monkeys from vaccine control group four
had detectable SIV-Gag-specific CD8 T cells by IFN-gamma
ELISPOT or tetramer staining.
Beta 7 integrin expression on SIV-Gag-specific CD8 T cells in
the peripheral blood does not differ between different vaccine
groups
Beta 7 integrin was detected on a significant proportion of
the SIV-Gag-specific CD8 T cells in the PB (see representa-
tive dot plots in Fig. 2). Alpha 4 beta 7 integrin must be
expressed on antigen experienced CD8 T cells in order for
them to adhere and migrate through gut blood vessels
(Butcher et al., 1999; Lefrancois et al., 1999). Therefore,
beta 7 integrin expression can serve as a marker of mucosal-
homing CD8 T cells on peripheral blood CD8 T cells. Beta 7
integrin expression was assessed on CD8 T cells concomi-
tantly with SIV-Gag tetramer binding, this enabled assess-
ment of beta 7 integrin on antigen-specific CD8 T cells as
well as the total CD8 T cell population in the PB. Firstly, the
CD8 T cells from monkeys with elevated binding of A01/
A02 SIV-Gag tetramer were examined (see Fig. 4). We
detected a range of (35–83%) of SIV-Gag-specific CD8 T
cells that co-express beta 7 integrin. Furthermore, the beta 7
integrin expression on these cells was predominantly at
moderate levels. There was no difference between vaccine
groups regarding the expression of beta 7 integrin on SIV-
Gag-specific CD8 T cells.CD8 T cells from immunized monkeys have an increased
frequency and expression of beta 7 integrin in the peripheral
blood
Next, the expression of beta 7 integrin was assessed on all
CD8 T cells in the peripheral blood. A sequential gating
technique was used to define T cells and then display beta 7
integrin expression on CD8 T cells (see Fig. 5). Beta 7
expression on CD8 T cells was separated into low, moderate
and high levels and the relative percentage in each group
recorded for all samples. Analysis of the frequency of CD8 T
cells with low, moderate or high beta 7 levels in the peripheral
blood demonstrated a change in a subset of the immunized
monkeys in CD8 T cells that express moderate or high levels
of beta 7 integrin (see Fig. 6), there was no apparent change in
the beta 7 low subgroup (data not shown). When CD8 T cells
with moderate beta 7 expression were assessed, a number of
immunized monkeys showed increasing frequency of this
phenotype from day 7 to day 14 post final Listeria boost.
Furthermore, many of these monkeys (with the increasing
frequency of CD8 T cells expressing beta 7 moderate) were
previously shown to have SIV-Gag-specific CD8 T cells
(arrowed in Fig. 6A). When the frequency of CD8 T cell
expressing high beta 7 integrin were assessed a similar picture
emerged. However, in this case, there was a preponderance of
immunized monkeys from group three that showed increasing
levels of beta 7 high CD8 T cells and were SIV-Gag specific
(arrowed in Fig. 6B). Interestingly, monkey 4123 (from
vaccine group three) had increased levels of CD8 T cells with
beta 7 integrinhi by day seven which subsequently dropped by
Fig. 4. Beta 7 integrin expression on SIV-Gag-specific CD8 Tcells in the peripheral blood does not differ between different DNA prime-Listeria boost vaccine groups.
Results show the frequency of SIV-Gag tetramer-positive CD8 T cells that co-express beta 7 integrin (black) or lack beta 7 integrin (white). Data are presented on SIV-
Gag tetramer (A01 or A02)-positive cells from day 7 (D7) or day 14 (D14) post-last Listeria boost. Also indicated are the monkey number and the vaccine group to
which individual monkeys belong.
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cells in the peripheral blood, gut tissue and axillary lymph
nodes.
When the beta 7 expression on CD8 T cells was examined
in the PB of pre-immunized monkeys there was no difference
in the frequency of beta 7 moderate or high CD8 T cells
compared to day 7 (data not shown). Further analysis of the
alpha chain expression coupled with beta 7 integrin on PB
CD8 T cells showed that the majority of beta 7 integrin-
positive CD8 T cells co-express the alpha 4 subunit (CD49d).
Furthermore, when the CD8 T cells were separated into beta 7
integrin moderate or high clusters we demonstrated that both
subgroups co-expressed alpha 4 as well as alpha-E (CD103)
subunits (see Fig. 6C). The population of CD8 T cells that
were beta 7/alpha-E positive is increased in frequency in the
beta 7 high cluster, although it is only a minor subgroup
compared to the gut-homing beta 7/alpha 4-positive CD8 T
cells.
Beta 7 integrin expression on CD8 T cells in the lymph nodes
When just SIV-Gag-specific CD8 T cells were assessed, beta
7 integrin was co-expressed in both the axillary and mesenteric
lymph nodes. Furthermore, these cells expressed beta 7 integrin
at moderate levels only (see examples in Fig. 3).
When the total CD8 T cell population in the mesenteric
lymph node was assessed for beta 7 integrin expression
there were (81–97%) CD8 T cells that were beta 7 integrin
positive (see Supplementary Fig. 1). The vast majority of
these CD8 T cells express beta 7 at moderate levels (67–
90%) and a smaller subset were beta 7hi (1–12%). Whenthe beta 7hi CD8 T cells were examined, six monkeys that
received the test vaccines had more than 5% CD8 T cells
with this phenotype. However, there was no difference in
the frequency of this phenotype between vaccine groups or
between monkeys that had SIV-Gag-specific CD8 T cells in
the mesenteric lymph node. In contrast, when the axillary
lymph nodes were examined, only two of the monkeys that
had received a test vaccine had beta 7hi CD8 T cells greater
than 5%. Nonetheless, the CD8 T cells harvested from
axillary lymph nodes do express beta 7 integrin at a high
frequency (78–98%) (see Supplementary Fig. 1).
Beta 7 integrin expression on gut CD8 T cells
Beta 7 integrin was investigated on both the IEL and LPL
fraction of jejunum and ileum tissue. Example dot plots of CD8
T cell beta 7 expression can be seen in Fig. 5 for each of these
gut tissues. These dot plots show some interesting features of
CD8 T cells from the gut. Firstly, all CD8 T cells from the IEL
and LPL fractions express beta 7 integrin. Secondly, in general,
CD8 T cells from the IEL fraction express beta 7 integrin at
higher levels than the LPL's. Furthermore, beta 7 integrin was
expressed at high levels on SIV-Gag tetramer-positive CD8 T
cells. More detailed analysis of the level of beta 7 expression on
ileal CD8 T cells can be seen in Fig. 7, the data for the jejunal
CD8 T cell fractions are similar (data not shown). The ileal IEL
fraction contains CD8 T cells which are largely beta 7hi, only
three monkeys immunized with the test vaccine had less than
50% CD8 T cells with the beta 7hi phenotype. In contrast, a
more heterogeneous expression of beta 7 integrin was observed
on CD8 Tcells from the ileal LPL fraction (see Fig. 7). While all
Fig. 5. Beta 7 integrin expression on CD8 Tcells differs between the peripheral blood, lymph nodes and the gut tissue. Dot plots from representative samples depict the
relative expression of beta 7 integrin on CD8 T cells isolated from peripheral blood(A), mesenteric or axillary lymph nodes and gut tissue (B). T cells were selected
based on expression of CD3 and a lymphocyte scatter gate.
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immunized monkeys' express predominantly beta 7 integrin at
moderate levels in the ileal LPL fraction.
Central and effector memory CD8 T cells are induced by a
DNA prime-Listeria boost strategy
The relative frequency of naive, central and effector CD8
T cells was evaluated in all peripheral blood, lymph node and
gut tissue samples using expression of CD28 and CD95 as a
phenotypic indicator of functional type. The phenotype for
these 3 functional subgroups in the lymphocytes of rhesus
macaques has been previously established by Pitcher et al.
(2002). In this study, they identified that CD8 T cells in the
PB can be divided into naive (CD28+/CD95−), effector
memory (CD28−/CD95+) and central memory (CD28+/
CD95+) cells. They identified these CD8 T cell subgroups
using intra-cellular cytokine staining for cytokines and co-
expression of CD markers following stimulation by the
superantigen SEB plus anti-CD49d or rhesus macaque CMV
IE-1 peptide mixes.In our study, the pattern of CD28 and CD95 expression on
CD8 T cells was identical to that reported by Pitcher et al. in the
peripheral blood, lymph nodes and the gut IELs (see Fig. 8 for
example dot plots). On day 7, the peripheral blood contains
largely naive CD8 T cells; however, the naive CD8 T cells
decrease in frequency from day 7 through to day 14 in
immunized monkeys, p=0.01 (see Fig. 9). Simultaneously, the
effector memory CD8 T cell population increased in the
peripheral blood from day 7 through to day 14 in most
immunized monkeys, p=0.06 (see Fig. 9). The frequency of
naive and effector CD8 Tcells in the PB samples of pre-immune
monkeys is similar to that seen on day 7 post last Listeria boost
(data not shown).
The frequency of naive, effector and central memory
CD8 T cell subsets in the lymph nodes of immunized
monkeys differed from peripheral blood. Naive CD8 T cells
are the major subgroup in the axillary and mesenteric lymph
nodes and range from (55–85%) of CD8 T cells (see
Supplementary Fig. 2). The central memory CD8 T cells are
the next most common subgroup in both sets of lymph
nodes and constitute (10–50%) of CD8 T cells. In contrast,
Fig. 6. CD8 Tcells expressing α4β7 integrin increase in the peripheral blood of some immunized monkeys from day 7 to day 14 post-Listeria boost. The percentage of
CD8 T cells expressing beta 7 integrin was monitored in the peripheral blood on days 7 and 14 after the final Listeria boost immunization. This graph represents the
frequency of CD8 T cells expressing beta 7 at high (A) or moderate (B) levels. CD8 T cells were selected based on co-expression of CD3 and CD8 and a lymphocyte
scatter gate. Arrows indicate monkeys with CD8 T cells positive for SIV-Gag tetramer binding and/or IFN-gamma ELISPOT. The integrin alpha chain co-expressed
with the beta 7 subunit was demonstrated in panel C. Representative dot plots in panel C depicting the alpha chain expression on CD8 T cells that are beta 7 integrin
positive (a), beta 7 moderate (b) and beta 7 high (c).
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cells with an effector memory phenotype (see Fig. 8 for
representative dot plots, and Supplementary Fig. 3 for
individual data) and a few (<5%) CD8 T cells with a central
memory phenotype. Statistical analysis (Mann–Whitney) of
the naive, effector and central memory CD8 T cell
frequency in the gut demonstrated a significant difference
( p=0.048) between the DNA+IL-15 versus DNA groups in
the ileum effector memory CD8 subset only. Otherwise,there was no difference in the frequency of naive, effector
or central memory CD8 T cells between vaccine groups in
the lymph node or gut tissue.
Discussion
Inducing a mucosal cell-mediated immune response has
become a clear aim for successful HIV vaccines. This is based
on knowledge that HIV is commonly transmitted across
Fig. 7. High beta 7 integrin expressing CD8 Tcells are prevalent at gut effector sites. The percentage of CD8 Tcells expressing beta 7 integrin at high, moderate or low
levels was monitored in the ileum, intraepithelial cells (A) and lamina propria lymphocytes (B) day 14 after the final Listeria boost immunization. CD8 T cells were
selected based on co-expression of CD3 and CD8 and a lymphocyte scatter gate, beta 7 expression on CD8 T cells was divided into either low, moderate or high levels
(as per Fig. 5). Arrows indicate monkeys with elevated numbers of CD8 T cells that express beta 7 at high levels and are positive for SIV-Gag tetramer and/or IFN-
gamma ELISPOT.
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active infection in memory CD4 T cells in the gut and depletes
them. This massive assault on the immune system in the gut
happens early in the infection before the virus is evident in the
periphery. Therefore, a successful vaccine should induce HIV-
specific CD8 T cells that would prevent the active replication of
the virus in the gut and avoid the subsequent elimination of CD4
T cells.
SIV infection in rhesus macaque monkeys has been
commonly used to model HIV infections in humans. In fact, a
series of studies have measured the mucosal cell-mediated
immune response to SIV vaccines (Baig et al., 2002; Cranage et
al., 1997; Cromwell et al., 2000; Evans et al., 2003; Imaoka et
al., 1998; Klavinskis et al., 1996; Lehner et al., 1999; Shacklett
et al., 2002; Sharpe et al., 2003; Wang et al., 2000) in rhesus
macaques. Two of these studies are noteworthy because the
vaccines initiate an immune response in different ways. The first
study uses a modified Salmonella vector with a type III
secretion system which targets antigens to the cytoplasm and
induces a CD8 T cell response (Evans et al., 2003). The second
study uses attenuated strains of SIV (administered i.v.), which
are thought to induce a mucosal immune response because the
virus replicates in the gut CD4 T cell population (Cromwell et
al., 2000). In this study, we used a novel Listeria vaccine vector
to deliver target antigens as a vaccine for SIV. Our current study
tested if we could amplify the mucosal CD8 T cell response toSIV by combining the DNA prime-oral Listeria with either IL-
15 or IL-12 plasmid vaccines. We designed the study to have 4
vaccine groups, three received the test SIV DNA vaccines with
or without IL-12 or IL-15. The control group received a DNA
prime-oral Listeria boost vaccine with irrelevant antigens.
Initially, SIV-Gag and Env-specific CD8 T cells were
demonstrated in the PB; however the Env responses decreased
sharply after the 1st Listeria boost. After completion of the
immunization schedule, we monitored the SIV-Gag CD8 T cell
response in the peripheral blood, lymph nodes and the gut. SIV-
Gag-specific CD8 T cells were demonstrated in the PB from
monkeys within all test vaccine groups on both days 7 and 14
post-last Listeria boost. The combination of ELISPOT and
tetramer data was more compelling for the DNA+IL-15 group
compared to the other test groups, in that there was a larger
number of responding monkeys in this group in the PB and the
axillary lymph node. Further examination of these SIV-Gag-
specific CD8 T cells in the PB demonstrated a variable
frequency of expression of the gut-homing molecule, beta 7
integrin. There was no difference in beta 7 integrin expression
on SIV-Gag CD8 T cells in the PB between vaccine groups.
Further characterization of the CD8 T cells in the PB revealed
that the beta 7 integrin-positive cells expressed the alpha 4
subunit, a minor subset also co-express alpha-E subunit. SIV-
Gag-specific CD8T cells were also demonstrated in gut tissue,
gut draining lymph nodes (mesenteric) and distant lymph node
Fig. 8. Gut tissue, lymph nodes and peripheral blood contain different proportions of naive and memory CD8 T cells. Dot plots from representative samples showing
(A) a peripheral blood sample with the gating procedure to define CD8 T cells and then CD95 versus CD28 expression to define the naive (N), central (C) and effector
(EM) memory cell. Dot plots in (B) show representative distribution of naive, central and effector memory cells in lymph nodes and gut tissue.
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expressed beta 7 integrin, but at varying density on the cell
surface. In the gut IEL fraction, and to a lesser extent the LPL
fraction, the SIV-Gag-specific CD8 T cells express beta 7
integrin at high levels. This most likely represents the co-
expression of two separate heterodimeric integrin molecules,
alpha-E as well as alpha 4 with beta 7 (Farstad et al., 1996).
Alpha 4 beta 7 is required for adhesion of the CD8 T cell to the
gut endothelium, this occurs via its ligand MadCAM-1 and
from this point the CD8 T cell can migrate into the gut lamina
propria (Andrew et al., 1996; Rott et al., 1996). Subsequently,
the CD8 T cell may also express alpha-E beta 7, a feature of
IELs, this enables the cell to bind E-Cadherin expressed by the
epithelial cells of the gut mucosa.
Interestingly, we also observed beta 7 integrin expression
on SIV-Gag-specific T cells in both the axillary and mesenteric
lymph nodes. Beta 7 integrin expression on CD8 T cells in
lymph nodes has been described in previous studies (Andrew
et al., 1996; Farstad et al., 1996; Pitcher et al., 2002), loss of
beta 7 integrin partially decreases migration to mesenteric
lymph nodes but does not affect migration to peripheral lymph
nodes (e.g., axillary lymph node) (Wagner et al., 1996). This
effect is due to the differential expression of ligands on the
high endothelial venules at the respective sites, mesentericlymph nodes express peripheral node addressin (L-selectin
ligand) and/or MadCAM-1 (alpha 4 beta 7 ligand) whereas
peripheral lymph node HEV only express peripheral node
addressin.
Our data describing the induction of SIV-specific CD8 T
cells in the PB, gut and lymph nodes is similar to that described
previously by other studies, which used a smaller number of
monkeys to test induction of mucosal immunity by a SIV
vaccine (Baig et al., 2002; Cromwell et al., 2000; Evans et al.,
2003; Sharpe et al., 2003). Cromwell et al. (2000) observed
SIV-Gag-specific CD8 T cells in response to an attenuated SIV
vaccine in PB and the gut. We have a similar frequency of SIV-
Gag-specific CD8 T cells as well as induction of both beta 7-
positive and -negative CD8 T cells to SIV-Gag in the PB. This
suggests that we have induced SIV-Gag-specific CD8 T cells
that have the capacity to home to mucosal and other effector
sites. In another study, a Salmonella vector was used to deliver
SIV-Gag (Evans et al., 2003) and was focused on mucosal
priming. Similar to the Listeria vector, this vector delivers
antigen to both MHC class I and II processing pathways
(Russmann et al., 1998). The authors demonstrated a SIV-Gag-
specific CD8 T cell response in 2 rhesus macaques that received
the Salmonella Gag plus MVA Gag boost, both these monkeys
had beta 7 integrin-positive and -negative SIV-Gag CD8 T cells
Fig. 9. Effector memory and naive CD8 Tcells alter in the peripheral blood after immunization. Effector memory and naive CD8 Tcells were assessed in the peripheral
blood on days 7 and 14 post-Listeria boost. Relative expression of CD95 and CD28 on CD8 T cells was used to define the effector memory (A) and naive (B) cells.
CD8 T cells were defined by scatter gates and co-expression of CD3 and CD8.
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the PB and colonic mucosa following i.m. immunization with
plasmid DNA containing the SIVmac239 gag, pol, nef genes
and HIV 89.6 env epitope genes boosted by MVA expressing
SIC gag-pol and HIV 89.6 (17 monkeys). In addition, Sharpe et
al. (2003) demonstrated SIV-Gag-specific CTL in mesenteric,
iliac and inguinal lymph nodes following intra-rectal immuni-
zation with HIVand SIV CTL epitope DNA in microparticles (3
monkeys). We have demonstrated a similar magnitude of SIV-
Gag-specific CD8 T cells in the periphery and the gut mucosa in
response to our vaccine in a larger group of monkeys and found
this response to be consistent across all test vaccine groups.
We have evidence of a CD8 T cell response to the SIV
vaccine in most monkeys in all test vaccine groups. Although
there was no marked difference in the final gut mucosal
response between vaccine groups there was a difference
detected in the PB during the priming phase of the study,
specifically after the 3rd DNA and 1st Listeria boost. This
suggests that the IL-15 or IL-12 plasmid may not be giving
additional benefit to the mucosal immune response to SIV
DNA-oral Listeria boost. However, it is possible that these two
cytokines could be inducing functionally different CD8 T cells.
Therefore, further studies could be done to examine the SIV-
Gag CD8 T cell functional phenotype (Betts et al., 2005) after
completion of the last oral Listeria boost as well as looking for a
memory response.In addition, we describe a change in the frequency of effector
memory and naive CD8 T cells in the PB in response to
immunization. Naive CD8 Tcells decrease and effector memory
CD8 T cells increase in response to immunization. The
frequency of naive and effector memory CD8 T cells in the
gut was similar to that described previously (Pitcher et al.,
2002). Although there was some individual variation (especially
in the gut lamina propria lymphocyte fraction), the only
significant change in the frequency of these functional CD8 T
cell subsets occurred in the ileum IEL fraction in response to the
DNA+IL-15 immunization.
In our previous study (Boyer et al., 2005b), a DNA prime-
Listeria boost vaccine-induced SIV-Gag and Env-specific T
cells. When the immunized monkeys were challenged with
SIVMac239, it was found the monkeys that received the DNA
prime-Listeria boost vaccine had significantly better control of
viral loads for a longer period than the control monkeys. In
this study, we characterized the mucosal CD8 T cell response
to the DNA prime-Listeria boost vaccine; because this
required sacrifice of the animals, it was not logistically
possible to simultaneously perform a SIV challenge in the
same group of immunized monkeys. Nonetheless, based on
the data from our prior study (Boyer et al., 2005b), we would
expect that following DNA prime-Listeria boost the monkeys
would be more resistant to SIVMac239 challenge than control
monkeys.
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oral Listeria boost strategy induces a mucosal SIV-Gag-specific
CD8 T cell response. We provided evidence of the SIV-Gag-
specific CD8 T cells circulating in the PB, many of which had
gut-homing capacity. Importantly, these antigen-specific CD8 T
cells were present in the gut, both the lamina propria and
between the epithelial cells of the gut mucosa. This SIV-specific
mucosal immunity has the potential to prevent SIV infection at
mucosal surfaces and limit the rapid expansion of SIV in the
gut.
Methods
Animals
Male and female Indian rhesus macaques (Macaca mulatta)
3–8 years old were evaluated at the start of the study. The rhesus
macaques were housed at Bioqual, Rockville, MD, under
USDA approved conditions. These facilities are accredited by
the American Association for the Accreditation of Laboratory
Animal Care International and meet National Institute of Health
standards as set forth in the Guidelines for Care and Use of
Laboratory Animals. Animals were tested for MHC class I SLA
expression by HLA/Molecular Diagnostics Laboratory at the
University of Wisconsin. They were assigned to different
vaccine groups as shown in Table 1 to evenly spread the
distribution of haplotypes.
Vaccines and immunization
DNA vaccines
The pCSIVenv and the pCSIVgag plasmids expressing the
SIV envelope and core protein, Gag, are Rev-independent
expression vectors that have been codon optimized for high
level expression as previously described (Nappi et al., 2001).
Codon optimization mutates the DNA sequence without
disrupting the amino acid sequence. Ultimately, there is
mutation or elimination of the RRE inhibitory sequence
which leads to the more abundant translation of tRNA. The
final construct was characterized by restriction digest and DNA
sequence.
The dual promoter IL-12 expression vector encodes the
macaque IL-12 p35 and p40 genes (Boyer et al., 2005a). The
rhesus IL-12 p35 subunit is expressed under control of the
HCMV immediate early promoter and SV40 polyadenylation
signal, whereas the rhesus IL-12 p40 subunit is expressed under
control of the simian CMV promoter (SCMV) and BGH
polyadenylation signal.
The cloning of the macaque IL-15 construct (Sequence from
GenBank, accession number U19843) into pVAX1 cloning
vector (Invitrogen, Carlsbad, CA) was carried out by PCR
amplification with the following 5′ to 3′ primers. Sense:
GCCCCCGTCGACGCCGCCACCATGAGAATTTCGAAA-
CCACATTTGAG, Antisense: ATCGGGCTCGAGTCAA-
GAAGT GTTGATGAACATTTGG. The features of pVAX1
cloning vector that make it suitable for use as a vector designed
for DNA vaccines include a CMV promoter for high-levelexpression in a wide range of mammalian cells, BGH
polyadenylation signal for efficient transcription termination
and polyadenylation of mRNA and kanamycin resistance gene
for selection in Escherichia coli. PCR conditions for all
reactions were 1 cycle at 97 °C for 3 min, 30 cycles at 94 °C
for 1 min, 55 °C for 75 s and 72 °C for 75 s, followed by final
extension at 72 °C for 10 min. The 488 base pair PCR product
was ligated into pVAX1 cloning vector following a restriction
enzyme digestion using EcoRI and XhoI that were designed
into the PCR primers and are in the multiple cloning region of
pVAX1. All positive clones were verified by sequence analysis.
Plasmids were purified by Puresyn (Malvern, PA). DNAwas
formulated in 0.15 M citrate buffer and 0.25% bupivicaine at a
pH of 6.5. Expression of the IL-12 (Boyer et al., 2005a) and IL-
15 (Kutzler M and Boyer J, unpublished observations) plasmid
constructs were demonstrated following transient transfection
of RD cells. RD cell supernatants were harvested after 72 h and
analyzed to verify the presence of IL-12 or IL-15 protein by
commercial ELISA assay.
Listeria vaccines
The recombinant Listeria monocytogenes vaccines used in
this study have been described in detail in a previous study
(Boyer et al., 2005b). Three Listeria constructs were used
for the oral boost segment of the immunization protocol,
Lm-Gag secretes SIV-Gag protein. Due to difficulties in
Listeria secreting SIV Env, two separate Listeria constructs
were made that together overlap the entire gp120 sequence.
Lm-SIV-Env-5′ expresses fragment residues 30–298 (no
signal sequence) and Lm-SIV-3′ expresses residues 198–
525 (Boyer et al., 2005b). Prior to their use all strains of
bacteria were mouse-passaged in order to stabilize their
behavior in vivo (Peters and Paterson, 2003). Expression of
the SIV proteins by recombinant Listeria was confirmed by
Western blot. The bacteria were propagated on BHI (Difco,
Detroit, MI), bacterial aliquots were stored at −70 °C. An
inoculum of bacteria was prepared for oral immunization by
thawing an aliquot and appropriately diluting it in sterile
PBS.
Immunization schedule
Four groups of Indian rhesus macaques were immunized as
outlined in Table 1. In three of the immunization groups, five
rhesus macaques were immunized i.m. at weeks 0, 4, 8 and 12
with 2 mg each of the pCSIVgag and pCSIVenv DNA plasmids.
The DNA immunizations were followed by four boosts with
recombinant L. monocytogenes at weeks 16, 20, 24 and 38. The
L. monocytogenes was delivered orally as an equal mixture of
1010 Lm-SIV-Gag and Lm-SIV-Env-5′ and -3′ providing a total
dose of 3×1010 bacteria for the first two immunizations and
3×1011 bacteria/dose for the final two immunizations. A
control group received 2 mg Variola DNA (genes A27L and
A4L) followed by three boosts with recombinant L. mono-
cytogenes expressing HPV-16 E7 (Gunn et al., 2001) at the
same time intervals as the test groups. Thirty minutes prior to
the oral immunization, monkeys were given Zantac (ranitidine
hydrochloride) 2.5 mg/kg i.m. The animal was then anesthetized
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CeraVacx Buffer was administered p.o. via a nasogastric tube.
Each dose of vaccine was thawed in 1 ml lots and administered
orally via the gastric tube.
Collection of samples and preparation of cells
Peripheral blood was collected during the immunization
schedule and on days 7 and 14 after the last oral Listeria
immunization. PBMCs were prepared by standard density
gradient centrifugation and a viable cell count performed.
On day 14 after the last oral Listeria immunization, a
necropsy was performed and tissue samples collected,
including axillary and mesenteric lymph nodes and 10 cm
segments of jejunum and ileum. Excision of the jejunum was
performed 30–40 cm distal to the pylorus to obtain proximal
jejunum tissue. Lymphocytes were isolated from the lymph
nodes following physical disaggregation and passing the cells
through a 70-μm sieve followed by a Tris-buffered ammo-
nium chloride lysis step. In contrast, lymphocytes were
isolated from the gut tissue to obtain intraepithelial lympho-
cytes (IEL) and lamina propria lymphocytes (LPL) as
described previously (Veazey et al., 1997). Briefly, each gut
tissue segment was incubated in 30 ml Hank's Balanced Salt
Solution (HBSS) containing 1.0 mM EDTA for 30 min at
37 °C in an orbital shaker. Supernatant was collected, the
cells were isolated by centrifugation and resuspended in
RPMI and stored on ice. The process was repeated with the
tissue samples and the harvested cells were pooled, washed in
calcium/magnesium-free PBS and resuspended in RPMI1640
medium containing penicillin, 25 mM HEPES buffer, 2 mM
L-glutamine and 5% FBS, these cells form the IEL fraction.
LPLs were collected by cutting the residual intestinal
segments into 1–2 mm pieces and transferring the tissue
into a flask of RPMI 1640 medium containing 0.75 mg/ml
collagenase (90 U/ml), penicillin, 25 mM HEPES buffer,
2 mM L-glutamine and 5% FBS. Flasks were incubated for
two 30 min periods at 37 °C; at the end of each interval,
intestinal pieces were further separated by repeated pipetting
with a 10-ml pipette. The resulting medium was passed
through a sieve (size 40 μm) to separate the tissue from the
LPLs. The IEL and LPL cell suspensions were further
enriched using a Percoll bilayer density gradient centrifuga-
tion. The Percoll gradient included 2 ml of 60% Percoll under
2 ml of 35% Percoll. The cell suspensions were layered over
the Percoll bilayers and centrifuged for 20 min at 1000×g.
Cells were harvested and washed and resuspended in RPMI
for immunological assessment.
Antibodies and tetramers
The following antibodies from BD Pharmingen were used
in this study CD8 (RPTA-8), beta 7 integrin (FIB504), CD3
(SP34-2), CD95 (DX2) and CD28 (CD28.2). In addition, the
antibodies CD8 beta (2ST8.5H7), CD103 or alpha-E (2G5)
and CD49d or alpha 4 (HP2/1) were provided by Beckman
Coulter.Two SIV-Gag tetramers, which were generously provided by
David Watkins (University of Wisconsin), were used in this
study, the CM9 tetramer (CTPYDINQM, Gag181–189) (Allen et
al., 1998; Kuroda et al., 1998) a MamuA*01 epitope and GY9
tetramer (GSENLKSLY, Gag71–79) (Vogel et al., 2002) a
MamuA*02 epitope.
Flow cytometry
Staining
Two sets of stains were performed on each sample. Firstly,
SIV-Gag tetramer binding to CD8 T cells was combined with
beta 7 integrin expression. Therefore, 106 cells were stained
with either APC-conjugated tetramer, CM9 (A01 haplotype
monkeys) or GY9 (A02 haplotype monkeys), for 1 h at 37 °C
followed by direct labeling with beta 7 integrin-PE, CD3-
PerCPCy5.5 and CD8-FITC. The second set of direct stains
were performed to define the CD8 T cells as either naive,
effector or central memory. In this case, 5×105 cells were
directly stained with CD95-FITC, CD28-PE, CD8-PECy7 and
CD3-APC.
In addition, a subset of peripheral blood samples were
prepared to characterize the alpha chain coupled with beta 7
integrin on CD8 T cells. These samples were stained by
CD8beta-PE, CD103-biotin, CD49d-FITC, integrin beta 7-
PECy5 followed by streptavidin-APC. Isotype controls for each
CD marker were included for all samples.
Data acquisition and analysis
Data were acquired on the BD FACSCalibur flow cytometer
using the CellQuest PRO software. List mode files were
analyzed using FlowJo (Tree Star Inc.), a sequential gating
strategy was used to define CD8 T cells before assessment of
tetramers or additional CD markers.
Tetramer analysis
Two forms of controls were used for analysis of the
tetramer binding to CD8 T cells. Firstly, each vaccination
group contained non-A01/A02 haplotype monkeys. In addi-
tion, group 4 monkeys received a non-SIV control vaccine.
The quadstat regions were set for each test sample based on
negative controls for the sample (isotype and ‘fluorescence
minus one’ controls) as well as non-A01/A02 monkeys
stained with the same batch and run on the same day. In
order to establish, a reference value for positive tetramer
binding, the mean value for tetramer binding to non-A01/A02
monkeys was calculated. A test sample was deemed
‘positive’ if the A01 or A02 tetramer binding was greater
than twice the mean of non-A01/A02 monkeys. This value
was established for both the A01 CM9 and A02 GY9
tetramers on samples collected days 7 and 14 post final
Listeria boost. For example, in PB samples day 7, the
positive cut-off for A01 tetramer CM9 binding to CD8 T
cells was 0.128% and the A02 tetramer GY9 binding was
0.156%, respectively. The same process was used to
determine the cut-off for A01 or A02 tetramer binding to
gut and lymph node samples.
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Peptides
One hundred and twenty-five peptides corresponding to the
entire coding region of SIVmac239 Gag and Env protein were
obtained from the AIDS Reagent Reference Repository (NIH).
These 15-mers overlapping by 11 amino acids were resus-
pended in DMSO at a final concentration of 100 μg/ml for
ELISPOT analysis.
ELISPOT
ELISPOT was performed using IFN-gamma reagents
purchased from MabTech (Sweden) and nitrocellulose plates
from Cellular Technologies (Cleveland Ohio). Plates were
coated with IFN-gamma capture antibody and incubated
overnight at 4 °C. After washing with sterile PBS, the peptide
pools were diluted 1:200 in culture medium (RPMI 1640
containing 2 mM L-glutamine, 100 IU/ml penicillin and 100 IU/
ml streptomycin and 10% fetal bovine serum) and 100 μl was
transferred into 3 wells. Cells in culture media were added to the
wells in triplicate at a concentration of 200,000 cells per well.
The plate was incubated for 24 h at 37 °C. Biotinylated antibody
at a concentration of 1 μg/ml was added and incubated
overnight at 4 °C. After washing, streptavidin-AP was added
at a concentration of 1 ng/ml and incubated for 2 h at room
temperature. Plates were washed with PBS. BCIP/NBT was
added and incubated until spots appeared. The reaction was
stopped. A positive response is defined as greater than 50 spot
forming cells (SFC) per 1 million PBMCs.
Depletion studies
A second set of PBMCs was depleted of CD8 lymphocytes
with anti-CD8 depletion beads according to manufacturer's
protocol (Dynal) before plating cells in triplicate with peptides
as described in the Methods section for the ELISPOT assay.
The ELISPOT protocol as described above was completed on
the PBMCs depleted of CD8 lymphocytes.
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